A widely criticized study that promoted hydroxychloroquine as a treatment for COVID-19 has been officially retracted, the Dutch publishing company Elsevier confirmed on Tuesday. The study, originally published in March 2020 in the International Journal of Antimicrobial Agents, has been flagged for violating ethical standards and issues related to its research methodology.
Elsevier’s decision to retract the study followed an investigation by its research integrity team and the International Society of Antimicrobial Chemotherapy (ISAC). The inquiry uncovered several critical concerns:
- Lack of Ethical Approval: The study could not confirm whether patients were enrolled before receiving ethical clearance.
- Equipoise Concerns: The journal found no evidence of genuine uncertainty within the medical community regarding the treatments compared in the study.
- Informed Consent Issues: Questions were raised about whether patients had given informed consent to receive azithromycin alongside hydroxychloroquine, despite azithromycin not being considered standard care at the time.
Three of the study’s authors—Johan Courjon, Valérie Giordanengo, and Stéphane Honoré—have publicly disassociated themselves from the paper, citing concerns about its methodology and conclusions. These authors requested the removal of their names from the study.
Other authors, however, have contested the retraction, disputing the investigation’s findings and the basis for withdrawing the paper.
The now-retracted study had significant influence, becoming the most-cited COVID-19 paper to be retracted and the second-most-cited retracted paper in history, according to Nature. Its publication spurred the U.S. Food and Drug Administration (FDA) to issue an emergency use authorization in 2020, allowing hydroxychloroquine to be stockpiled and administered to hospitalized COVID-19 patients.
The drug gained further attention when then-President Donald Trump publicly endorsed it as a “miracle cure” and revealed he was using it as a preventive measure.
However, subsequent research contradicted these claims. A 2024 study published in Biomedicine & Pharmacotherapy found that COVID-19 patients who took hydroxychloroquine were 11% more likely to die compared to those who did not use the drug.
The French Society of Pharmacology and Therapeutics condemned the study, labeling it an example of scientific misconduct. The organization accused the researchers of manipulating data and biasing results to falsely promote hydroxychloroquine’s effectiveness.
“This study contributed to a global scandal,” the society stated. “Its promotion led to the overprescription of hydroxychloroquine, exposing millions to unnecessary risks and possibly causing thousands of preventable deaths. The principle of ‘first, do no harm’ was ignored, with devastating consequences.”
The retraction highlights the importance of rigorous peer review and adherence to ethical standards in medical research. As the fallout from the hydroxychloroquine controversy continues, experts emphasize the need for transparency and caution in presenting scientific findings, particularly during global health crises.
No comments:
Post a Comment